BIO Announces Presenting Companies for 11th Annual BIO Investor Forum
Washington, D.C. (September 6, 2012) – The Biotechnology Industry Organization (BIO) announces the initial list of presenting companies for the 11thAnnual BIO Investor Forum, an international investor forum which explores investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2013. The event will take place October 9-10, 2012 at the Palace Hotel in San Francisco, Calif.
“The aim of the BIO Investor Forum is to bring together a select group of private and early stage biotech companies along with leading investors in an effort to establish relationships and foster the development of new partnerships and, ultimately, new medicines. This year, we already have an exciting line-up of companies who will present their innovative products and technologies, from emerging public companies working on late-stage clinical trials, to newly-established Discovery companies developing novel biologics platforms,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO.
Companies were chosen through a competitive screening process with input from BIO and the event’s advisory committee. The committee is comprised of members from top-tier firms focused on investing and banking in the life sciences industry in addition to executives from emerging and leading biotech companies.
The following companies will present at the 11th Annual BIO Investor Forum:
Private:
- Acetylon Pharmaceuticals
- Affimed Therapeutics AG
- AlloCure Inc.
- Altheus Therapeutics
- Ambit Biosciences
- bluebird bio
- Celtaxsys
- Ceregene
- Chimerix
- Collegium Pharmaceutical
- Colucid Pharmaceuticals
- Contrafect Corporation
- Cylene Pharmaceuticals
- Dicerna Pharmaceuticals
- Epizyme
- FORMA Therapeutics
- Galleon Pharmaceuticals
- GlycoMimetics
- Immune Design Corp.
- Immune Targeting Systems Ltd.
- Intarcia Therapeutics
- Intrexon Corporation
- KemPharm, Inc.
- KineMed
- Lipocine
- MabVax Therapeutics
- Metabolex
- Metabolon
- Midatech Group Ltd.
- Neurotez
- NexBio
- NOXXON Pharma AG
- Profil Institute for Translational Medicine
- Promedior
- Prosensa Therapeutics
- ProtAffin Biotechnologie AG
- Protagonist Therapeutics, Inc.
- Proteostasis Therapeutics
- Sage Therapeutics
- Sutro Biopharma
- Tetraphase Pharmaceuticals
- TheraVida
- TissueGene
- Trellis Bioscience, LLC
- Ultragenyx Pharmaceutical
- Zafgen
- Zosano Pharma
Public:
- AcelRx Pharmaceuticals
- Addex Therapeutics
- Advaxis
- ADVENTRX Pharmaceuticals
- Allon Therapeutics
- Aradigm Corporation
- Astex Pharmaceuticals
- Benitec Biopharma Ltd.
- Bio-Path Holdings
- BioSante Pharmaceuticals
- Circadian Technologies Limited
- Cyclacel Pharmaceuticals
- Durata Therapeutics
- Galena Biopharma
- GenVec
- Horizon Pharma
- Immunovaccine
- Karolinska Development AB
- MEI Pharma
- Resverlogix Corp.
- Senesco Technologies
- Sophiris Bio
- Spectrum Pharmaceuticals
- SymBio Pharmaceuticals Limited
- Threshold Pharmaceuticals
- Transgene SA
- Tranzyme Pharma
- ZIOPHARM Oncology
Now a staple at the Investor Forum, the event will once again feature a series of Discovery Track presentations. The presentations will focus on Seed and A-round companies incorporated after 2007 that have raised less than $25M total through October 2012. Companies in this track are also first-time presenters and use biotechnology or related technologies for research and development of drug products or diagnostics.The following companies are scheduled to present in the Private – Discovery Track:
- Applied Microarrays
- Arrogene
- Déclion Pharmaceuticals
- Eqalix
- HeatFlow Technologies
- Immunome
- Immunomic
- Inception Sciences
- InnoBioscience
- LoneStar Heart, Inc.
- NTpharma LLC
- Omniox
- Regenesance BV
- Retrophin LLC
- Serina Therapeutics
- Susavion Biosciences, Inc.
- Tunitas Therapeutics
- Wellesley Pharmaceuticals
- Xalud Therapeutics
Check back often as new presenters are continuously being added. If you are interested in becoming a presenter, please submit an application here.
The BIO Investor Forum is a must attend event for public and private market investors, research analysts, investment bankers, and industry executives focused on investment and business development opportunities in the life sciences. BIO One-on-One Partnering™ will also provide an opportunity to arrange meetings between investors; companies; and industry business development, licensing and therapeutic franchise heads.
To learn more about the BIO Investor Forum, including registration and program information, please visit here. Registration is complimentary for credentialed members of the media and qualified investors.
BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including Supporting Banks Stifel, Nicolaus & Company, and Roth Capital. BIO Double Helix and Helix Sponsors include Abbott Biotech Ventures, Amgen Ventures, Baxter Ventures, J&J Development Corporation, MedImmune Ventures, GlaxoSmithKline, Merck, and Pfizer.
###